DIALYSIS-TIR Study

Phase 4

Recruiting

• Conditions: End Stage Renal Disease on Dialysis; Type 2 Diabetes
• Interventions: Drug: Placebo; Drug: Semaglutide

• Registration Number: NCT06042153
• Lead Sponsor: University of Texas Southwestern Medical Center

Brief Summary

This study will look at control of blood sugar levels in persons with type 2 diabetes mellitus currently on chronic dialysis. Researchers will compare blood sugar levels in people taking semaglutide to people taking "dummy" medicine. The treatment participants get will be decided randomly.

Participants will need to inject the study medication once a week. The study will last for 1 year and a month. Participants will be asked to wear a sensor that measures blood sugar levels for a period of 10 days at five different time points during the study.

Detailed Description

The researchers also have a Data Safety Monitoring Plan in place.

Study Timeline

• Study First Submitted: 2023-09-11
• Study First Submitted QC: 2023-09-11
• Study First Posted: 2023-09-18
• Study Start: 2023-12-05
• Status Verified: 2024-02
• Last Update Submitted: 2024-02-11
• Last Update Posted: 2024-02-13
• Primary Completion: 2025-09
• Study Completion: 2026-09

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 157

Inclusion Criteria

1. Ability to provide informed consent before any trial-related activities. Trial-related activities are any procedures that are carried out as a part of trial, including activities to determine suitability for the trial.
2. Male or female Adults (age > 18 years at the time of signing the consent)
3. Type 2 diabetes mellitus diagnosed > 6 months prior to screening
4. On current chronic treatment with Hemodialysis or Peritoneal dialysis for > 6 months prior to screening
5. Current treatment with any glucose lowering pharmacotherapy, at a stable dose for at least 30 days. DPP-4 Inhibitors will be allowed at study entry and will be stopped at randomization.
6. Minimum of 80% valid data on the 10-day Continuous Glucose Monitor download
7. Time in Range 15 to 60%

Read More

Exclusion Criteria

1. BMI < 23 kg/m2 at screening
2. Current (within the past 90 days of screening) use of any GLP-1 RA
3. Personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia type 2
4. Known or suspected hypersensitivity to GLP-1 RA (trial medication(s), excipients, or related products)
5. Pregnant, breast-feeding or the intention of becoming pregnant, or not using effective contraceptive measures
6. Active weight loss, defined as weight loss of >5% of body weight in the past 3 months
7. Current participation in other interventional trials or last dose of any investigational product within 4 half- lives at the time of randomization
8. Any medical condition which in the judgement of the investigator precludes safe participation in the trial (includes, but not limited to active neoplasm, severe heart failure, recent cardiovascular event, severe frailty, planned cardiac or vascular surgeries on the day of screening etc)
9. If weight loss is not desired by the participant, or if the provider or investigator considers intentional weight loss to be detrimental to the health of the participant
10. Other or secondary forms of diabetes (like type 1 diabetes, pancreatogenic diabetes mellitus, MODY, LADA, drug induced, etc.)
11. Current diagnosis of gastroparesis or enteropathywhich in the opinion of investigator precludes safe treatment with GLP-1 RA.
12. Hypoglycaemia unawareness, or history of frequent or severe hypoglycaemia (in the opinion of the investigator)
13. Personal history of chronic pancreatitis, or acute pancreatitis within 180 days of screening
14. Known current uncontrolled or unstable retinopathy (by medical history)

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Arm 2- Placebo	Placebo	Participants will receive placebo (semaglutide) as an adjunct to standard-of-care.
Arm 1 - Semaglutide	Semaglutide	Participants will receive semaglutide as an adjunct to standard-of-care.

Primary Outcome Measures

Name	Time	Method
Change in TIR (70-180 mg/dl)	Baseline, 52 weeks	Measured in percentage by Continuous glucose monitor (CGM)

Secondary Outcome Measures

Name	Time	Method
Proportion of participants with TIR 70-180 mg/dl with more than equal to 5% improvement from baseline	52 weeks	Measured in percentage by CGM
Change in waist circumference	Baseline, 52 weeks	Measured in centimeters
Change in percentage total body fat	Baseline, 52 weeks	Measured in percentage
Change in percentage lean mass	Baseline, 52 weeks	Measured in percentage
Total score of EQ-5D-5L	52 weeks	The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.; The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement. Possible scores range from 0-100, where higher score indicate better outcome
Proportion of participants with Time below range <70 mg/dL for <4% of each day	52 weeks	Measured in percentage by CGM
Proportion of participants with >10 points improvement in % TIR 70-180 mg/dL without an increase in time below range <54 mg/dL of >0.5%	52 weeks	Measured in percentage
Proportion of participants with Time below range <54 mg/dL for <1% of each day	52 weeks	Measured in percentage by CGM
Change in haemoglobin A1c (HbA1c)	Baseline, 52 weeks	Measured in percentage
Number of participants with Severe hypoglycemia	52 weeks	Measured in count
Number of participants hospitalized	52 weeks	Measured in count
Total number of days spent in hospital	52 weeks	Measured in count
Total score of Diabetes Treatment Satisfaction questionnaire	52 weeks	Patient reported outcomes is assessed by Diabetes Treatment Satisfaction Score questionnaire which assesses patient satisfaction with diabetes treatment. It is composed of eight questions, each of which is scored by patients on a scale ranging from zero (e.g., "very dissatisfied", "very inconvenient") to six (e.g., "very satisfied", "very convenient"). Treatment satisfaction is assessed as the sum of the scores of the six questions on the first factor, with a higher score indicating higher treatment satisfaction.
Total daily dose of insulin	52 weeks	Measured as units/day
Change in body weight	Baseline, 52 weeks	Measured in kilograms
Total score of Kidney disease QoL short form	52 weeks	The KDQOL-SF is a self-report measure developed for individuals with kidney disease and those on dialysis. It is a shorter version of a measure developed by the same authors. It includes 43 kidney disease-targeted items, such as the effects of the disease of activities of daily living, work status, and social interaction, and 36 items that provide a measure of physical and mental health, and 1 overall health rating item ranging from 0 ("worst possible health") to 10 ("best possible health.").
Change in Inter-dialysis weight gain	Baseline, 52 weeks	Measured in kilograms
Change in Time in high range (180-250 mg/dl)	Baseline, 52 weeks	Measured in percentage by Continuous glucose monitor (CGM)
Change in Time in very high range (>250 mg/dl)	Baseline, 52 weeks	Measured in percentage by Continuous glucose monitor (CGM)
Change in Time in low range (54-69 mg/dl)	Baseline, 52 weeks	Measured in percentage by Continuous glucose monitor (CGM)
Change in Time in very low range (<54 mg/dl)	Baseline, 52 weeks	Measured in percentage by Continuous glucose monitor (CGM)
Proportion of participants with TIR 70-180 mg/dl for 70% of the day	52 weeks	Measured in percentage by CGM
Proportion of participants with Time above range >180 mg/dL for <25% of each day	52 weeks	Measured in percentage by CGM
Number of oral glucose lowering agents	52 weeks	Measured as count
Proportion of participants with mean glucose <154 mg/dL and <1% time below range <54 mg/dL	52 weeks	Measured in percentage

Trial Locations

Locations (5)

Davita UT Southwestern - Oak Cliff; 🇺🇸 Dallas, Texas, United States

University of North Carolina; 🇺🇸 Chapel Hill, North Carolina, United States

DaVita UT Southwestern - East Dallas; 🇺🇸 Dallas, Texas, United States

DaVita UT Southwestern - Preston; 🇺🇸 Dallas, Texas, United States

DaVita UT Southwestern - Irving; 🇺🇸 Irving, Texas, United States